Alvotech doses first patient in AVT04 (proposed ustekinumab) trials

Jul 6, 2021

Alvotech announced that the first patient has been dosed in the comparative, confirmatory efficacy and safety clinical study for AVT04 (proposed ustekinumab biosimilar). The trial is being conducted in Central and Eastern Europe and approximately 530 patients are expected to be enrolled in the study.

Print Page Mail Article